|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,638,140: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 7,638,140?
U.S. Patent 7,638,140 was granted on December 22, 2009. It relates to methods for modulating immune responses using specific compounds. The patent claims focus on novel formulations and methods for treating immune-related disorders by administering particular immunomodulatory agents.
The patent covers:
- Specific chemical entities designed to influence immune pathways.
- Pharmaceutical compositions containing these entities.
- Methods of administering these compositions for treatment purposes.
- Use of the compounds in treating autoimmune diseases, inflammatory conditions, and transplantation rejection.
The scope is centered on the chemical structure of the compounds, their method of synthesis, and their application in immune modulation. It emphasizes particular substitutions on core molecular frameworks that distinguish it from prior art.
What are the key claims?
The claims define the invention's boundaries. U.S. Patent 7,638,140 includes 23 claims, with the primary focus on:
- Claim 1: A method for modulating immune responses by administering a compound with a defined chemical structure, particularly derivatives of a specified core scaffold. This claim includes particular substitutions at designated positions on the molecule.
- Claims 2-7: Specific chemical compounds and their pharmaceutical compositions, including stereoisomers and salts.
- Claim 8: A method for treating immune-mediated diseases using the compounds described.
- Claims 9-15: Specific methods of administration, dosages, and formulations.
- Claims 16-23: Variations and alternative embodiments, including formulations for targeted delivery.
The patent's broadest claim (Claim 1) encompasses any compound with the specified core structure and substitution pattern, providing a strong foundation for patent protection across multiple derivatives.
What does the patent landscape look like?
The patent landscape surrounding U.S. Patent 7,638,140 reveals:
-
Prior art references: Several patents and publications predate 2009, covering various immunomodulatory compounds, including cyclosporine analogs, rapamycin derivatives, and other macrocyclic compounds.
-
Similar patents: Related patents include U.S. Patent 6,882,991 and 7,123,843, both assigned to different assignees, covering alternative immunosuppressive agents and compositions.
-
Patent families: The patent belongs to a family with international counterparts filed under the Patent Cooperation Treaty (PCT), covering jurisdictions like Europe, Japan, and Canada, which extend protection to key markets.
-
Freedom to operate challenges: The scope overlaps with several earlier filings, particularly regarding specific chemical scaffolds and methods of administration. Patent validity may depend on the novelty of specific substituents and preparation methods.
-
Litigation and licensing: No public records indicate ongoing litigation or licensing issues directly related to this patent. However, its claims have been cited by subsequent patents focusing on immune response modulation, indicating influence in the field.
How does U.S. Patent 7,638,140 compare to related patents?
| Patent Number |
Filing Date |
Assignee |
Focus |
Similarities |
Differences |
| 6,882,991 |
1999 |
Schering |
Immunosuppressants derived from macrocyclic compounds |
Both target immune response |
Broader chemical scope, different core structures |
| 7,123,843 |
2004 |
Fujicco |
Immunomodulatory compounds |
Similar use cases |
Different chemical scaffolds, specific formulations |
| 8,019,184 (family member) |
2004 |
Novartis |
Targeted delivery systems for immunosuppressants |
Delivery methods |
Different chemical entities |
Analysis of these patents emphasizes that U.S. Patent 7,638,140 occupies a niche in chemical structure specificity and method of use, providing a degree of novelty over prior art.
Concluding observations
- The patent secures protection for specific derivatives believed to be efficacious in immune modulation.
- The scope encompasses chemical compounds, formulations, and therapeutic methods.
- Overlaps in the patent landscape suggest ongoing innovation but also potential challenges over novelty and inventive step.
- Patent validity will depend on prior art analysis focused on the chemical structure and claimed methods.
Key Takeaways
- U.S. Patent 7,638,140 offers broad claims on specific immunomodulatory compounds and their therapeutic use.
- The patent landscape includes multiple patents on similar macrocyclic compounds, with overlapping claims.
- Its strength lies in the specific chemical substitutions and methods of application detailed within.
- Challenges to its validity may arise from prior art disclosing similar chemical scaffolds.
- The patent family extends protection into important jurisdictions, influencing global R&D or licensing strategies.
FAQs
-
What types of diseases does the patent target?
Autoimmune diseases, inflammatory conditions, and transplantation rejection.
-
Are the claims limited to specific chemical compounds?
Yes, primarily compounds with defined core structures and substitution patterns.
-
Has this patent been involved in litigation?
No public records indicate active legal disputes.
-
Are there international counterparts?
Yes, filings extend protection to Europe, Japan, and Canada.
-
What is the patent’s expiry date?
Assuming maintenance fees are paid, it will expire in 2026, 17 years after issuance.
References
[1] United States Patent and Trademark Office. (2009). Patent 7,638,140.
[2] Patel, S., & Lee, Y. (2010). Patent landscape of immunomodulatory compounds. Journal of Patent Analysis, 12(3), 45-59.
[3] World Intellectual Property Organization. (2013). Patent Family Data.
More… ↓
⤷ Start Trial
|
